QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.108.149724v1 329/1/159    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bawolak, M.-T. Articles by Marceau, F. Search for Related Content PubMed PubMed Citation Articles by Bawolak, M.-T. Articles by Marceau, F.

CELLULAR AND MOLECULAR

Fluorescent Ligands of the Bradykinin B₁ Receptors: Pharmacologic Characterization and Application to the Study of Agonist-Induced Receptor Translocation and Cell Surface Receptor Expression

Centre de Recherche en Rhumatologie et Immunologie, Centre Hospitalier Universitaire de Québec and Department of Medicine, Université Laval, Quebec, Canada (M.-T.B., G.M., J.B., F.M.); Department of Biochemistry, University of Colorado Denver, Aurora, Colorado (L.G., J.M.S.); Centre de Recheche en Infectiologie, Centre Hospitalier Universitaire de Québec, Quebec, Canada (L.-A.G., R.L.); and Faculty of Pharmacy, Université de Montréal, Montreal, Canada (A.A.)

Unlike the widely distributed and preformed B₂ receptors, the bradykinin B₁ receptors exhibit a highly regulated expression and minimal agonist-induced endocytosis. To evaluate the potential usefulness of fluorescent B₁ receptor probes applicable to live cell microscopy and cytofluorometry, combined chemical synthesis and pharmacologic evaluation have been conducted on novel 5(6)-carboxyfluorescein [5(6)CF]-containing peptides. Representative agents are the antagonist B-10376 [5(6)CF--aminocaproyl-Lys-Lys-[Hyp³, CpG⁵, D-Tic⁷, CpG⁸]des-Arg⁹-bradykinin] and the agonist B-10378 [5(6)CF--aminocaproyl-Lys-des-Arg⁹-bradykinin]. B-10376 has a K_i of 10 to 20 nM to displace [³H]Lys-des-Arg⁹-bradykinin from rabbit or human recombinant B₁ receptors expressed in human embryonic kidney (HEK) 293 cells and is a surmountable antagonist in the rabbit aorta contractility assay (pA₂, 7.49). B-10378 was a full agonist at the naturally expressed B₁ receptor (rabbit aorta contraction, calcium transients in human smooth muscle cells) and had a binding competition K_i of 19 or 89 nM at the recombinant rabbit or human receptor, respectively. Both fluorescent probes can label with specificity human or rabbit B₁ receptors expressed in HEK 293 cells (epifluorescence or confocal microscopy), but the agonist was associated with discontinuous plasma membrane labeling, which coincided with that of a red-emitting caveolin-1 conjugate. Cytofluorometry with B-10376 was applied to recombinant and, in human vascular smooth muscle cells, to naturally expressed B₁ receptors. In all fluorescent applications, the specific labeling was reduced by an excess of a B₁ receptor nonpeptide antagonist. Despite the loss of affinity determined by the introduction of a fluorophore in B₁ receptor agonist or antagonist peptides, the resulting agents allow original applications (imaging in live cells, cytofluorometry).

Address correspondence to: Dr. François Marceau, Centre de Recherche en Rhumatologie et Immunologie, Room T1-49, Centre Hospitalier Universitaire de Québec, 2705 Laurier Blvd., Quebec, QC, Canada G1V 4G2. E-mail: francois.marceau{at}crchul.ulaval.ca